We have located links that may give you full text access.
Symptomatic myopathies in sarcoidosis: disease spectrum and Myxovirus resistance protein A (MxA) expression.
Rheumatology 2022 November 29
OBJECTIVES: Symptomatic myopathy in sarcoidosis patients is not always due to sarcoid myopathy (SM). We investigated the clinical and pathological spectrum including myxovirus resistance protein A (MxA) expression among sarcoidosis patients.
METHODS: We reviewed the Mayo Clinic database (May 1980 - December 2020) to identify sarcoidosis patients with myopathic symptoms and pathological evidence of myopathy.
RESULTS: Among 5,885 sarcoidosis patients, 21 had symptomatic myopathy. Eight carried a diagnosis of sarcoidosis 5.5 years (median) prior to myopathy onset. Eleven patients had SM. The remaining had non-sarcoid myopathies (5 IBM, 1 immune-mediated necrotizing myopathy, 1 nonspecific myositis, 2 nonspecific myopathy and 1 steroid myopathy). Estimated frequency of IBM is 85 per 100 000 sarcoidosis patients. The following features were associated with non-sarcoid myopathies (p< 0.05): 1) predominant finger flexor and quadriceps weakness, 2) modified Rankin scale (mRS) >2 at time of diagnosis, 3) creatine kinase > 500 U/l, and 4) absence of intramuscular granulomas. Sarcoplasmic MxA expression was observed in scattered myofibers in 3 patients, 2 of whom tested for dermatomyositis-specific autoantibodies and were negative. Immunosuppressive therapy led to improvement in mRS ≥ 1 in 5/10 SM, none of the 5 IBM, and 3/3 remaining patients with non-sarcoid myopathies.
DISCUSSION: Symptomatic myopathy occurred in 0.36% of sarcoidosis. IBM was the second most common cause of myopathies after SM. Frequency of IBM in sarcoidosis is higher than general population. Recognition of features suggestive of alternative etiologies can guide proper treatment. Our findings of abnormal MxA expression warrants a larger study.
METHODS: We reviewed the Mayo Clinic database (May 1980 - December 2020) to identify sarcoidosis patients with myopathic symptoms and pathological evidence of myopathy.
RESULTS: Among 5,885 sarcoidosis patients, 21 had symptomatic myopathy. Eight carried a diagnosis of sarcoidosis 5.5 years (median) prior to myopathy onset. Eleven patients had SM. The remaining had non-sarcoid myopathies (5 IBM, 1 immune-mediated necrotizing myopathy, 1 nonspecific myositis, 2 nonspecific myopathy and 1 steroid myopathy). Estimated frequency of IBM is 85 per 100 000 sarcoidosis patients. The following features were associated with non-sarcoid myopathies (p< 0.05): 1) predominant finger flexor and quadriceps weakness, 2) modified Rankin scale (mRS) >2 at time of diagnosis, 3) creatine kinase > 500 U/l, and 4) absence of intramuscular granulomas. Sarcoplasmic MxA expression was observed in scattered myofibers in 3 patients, 2 of whom tested for dermatomyositis-specific autoantibodies and were negative. Immunosuppressive therapy led to improvement in mRS ≥ 1 in 5/10 SM, none of the 5 IBM, and 3/3 remaining patients with non-sarcoid myopathies.
DISCUSSION: Symptomatic myopathy occurred in 0.36% of sarcoidosis. IBM was the second most common cause of myopathies after SM. Frequency of IBM in sarcoidosis is higher than general population. Recognition of features suggestive of alternative etiologies can guide proper treatment. Our findings of abnormal MxA expression warrants a larger study.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app